DHR vs LLY
DHR: Danaher is a diversified conglomerate providing scientific instruments, diagnostics, and industrial solutions across life sciences, environmental monitoring, product identification, and healthcare globally. LLY: Eli Lilly is a global pharmaceutical innovator leading the market in metabolic health, including diabetes and obesity treatments, alongside a diverse portfolio of oncology and immunology therapies.
Side-by-side fundamentals
| Metric | DHR | LLY | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $215.11 | $1,246.93 | |
| Market cap as of 2026-08-24 | $151.2B | $1.17T | |
| P/E as of 2026-08-24 | 38.19 | 41.85 | DHR lower |
| PEG as of 2026-08-24 | 3.74 | 1.48 | LLY lower |
| Net margin as of 2026-08-24 | +15.9% | +33.5% | LLY higher |
| Gross margin as of 2026-08-24 | +58.6% | +83.4% | LLY higher |
| Operating margin as of 2026-08-24 | +20.4% | +42.2% | LLY higher |
| ROE as of 2026-08-24 | +7.7% | +92.6% | LLY higher |
| ROA as of 2026-08-24 | +4.7% | +22.0% | LLY higher |
| Debt / equity as of 2026-08-24 | 0.51 | 1.62 | DHR lower |
| Revenue growth (YoY) as of 2026-08-24 | +4.6% | +49.6% | LLY higher |
| Revenue CAGR (3y) SEC XBRL | -2.7% | +31.7% | LLY higher |
| Dividend yield as of 2026-08-24 | +0.5% | +0.8% | LLY higher |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-24 | 0.77 | 0.55 | |
| 1-year return as of 2026-08-24 close | +1.6% | +75.2% | LLY higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.